1113 results about "Prostatitis" patented technology

In a method for diagnosis and treatment of a patient with a tumor relating to prostate cancer, the following steps are implemented. A differential diagnosis of prostate cancer versus prostatitis and/or BPH is conducted on a patient using a cost-effective diagnosis method. If prostate cancer is diagnosed in the patient using a cost-effective measurement method, a characteristic value for the tumor aggressiveness of the prostate cancer is determined. A watchful waiting treatment is implemented with the patient given a characteristic value below a predeterminable first limit value. The size and position of the tumor is determined using a cost-effective method given a characteristic value above the first limit value. A cost-effective ultrasonic theranosis or a conventional therapy is conducted for a size below a second predeterminable limit value. The presence of metastases in the patient is checked, with a cost-intensive method generating image information, for a size above the second limit value. A metastasis treatment is implemented in the event that metastases are present. In the event that no metastases are present, a tumor treatment based on the aforementioned image information generated is implemented.

A composition providing an all-natural, non-surgical preventative of or improvement to disorders of the prostate gland is described. The invention relates to a composition for the prevention of or improvement of prostatitis, and for relieving symptoms and improving objective signs of prostatitis. The formula of the composition preferably includes the following ingredients each in a therapeutically effective amount: Vitamin C, Vitamin B6, Vitamin E, zinc, glycine, L-alanine, Glutamic acid, Saw palmetto, Pygeum extract, Pumpkin seed, Stinging nettle, Echinacea, garlic, Ginkgo leaves, and selenium.

The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.

Methods, systems, and computer program products for providing thermal therapies or internal thermal massage therapy for treating prostatitis by expanding and contracting a treatment balloon with inflation media and currently applying heat to a portion of the prostatic urethra.

This invention relates to a composition and method for treating diseases and disorders of the prostate such as prostatitis, benign prostatic hypertrophy, and prostate carcinoma. The prostate is treated by intraprostatic injection of a biodegradable sustained release formulation. By injecting the treatment substance directly into the prostate, improved treatment results are obtained with a much lower treatment substance dosage. Additionally, by incorporating the treatment substance into a biodegradable sustained release formulation, the need for frequent repetition of injections is eliminated.

The invention discloses a traditional Chinese medicine preparation for treating prostate disease, frequency of micturition, muscle swelling pain, impotence, prospermia and the like, which is characterized in that the preparation is prepared by the following raw material drugs by weight part: panax notoginseng 5-10, gallnut 10-20, rhubarb 10-15, catechu 10-15, coptis 10-20, scutellaria prepared tag 10-15, dodder 10-15, herba epimedii 10-20, eucommia bark 10-20, rhizome anemarrhenae 10-20, rehmannia glutinosa libosch 10-15, alisma 10-15, cortex moutan 10-15, Tuckahoe 10-15, prepared fleece-flower root 10-15, rhizome polygonati 10-20,rattanpalm 10-20, salvia miltiorrhiza 10-20, Chinese yam 10-20, peach kernel 10-20, safflower 10-20, foeniculum vulgare 5-10, fructus meliae toosendan 5-10, radix linderae 10-15, red paeony root 10-15, boneset 10-15, dandelion 10-30, radix codonopsitis 10-15, sauted Atractylis ovata 10-15, adlay 10-15, fructus amomi 10-15, alisma 10-20, angelica 10-20, leonurus 10-20, dried orange peel 10-20, akebia stem 10-20, plantain seed 10-30, knotgrass 10-30, herba dianthi 10-30, talcum 10-30, gardenia rhubarb 10-30, licorice 10-30, purslane 10-30, officinal magnolia bark 10-30, platycodon root 10-30, motherwort 10-30, self-heal 10-30, eucommia bark 10-15, boxthorn fruit 10-15, Japanese fern spore 10-15, root of rehmannia 10-15, wild celery 10-30, black lotus seed 10-30, fructus alpiniae oxyphyllae 10-30, pepper 10-30, cornu cervi 10-30, hoantchy root 10-30, leek seed 10-20, epimedium 10-20, radix morindae 10-20, phellodendron amurense white paeony root 10-30, radix codonopsitis 10-30, aconite 10-30, radix morindae 10-30, broomrape 10-30, schisandra 10-30, boxthorn fruit 10-30, dodder 10-30, curculigo orchioides 10-30, dogwood 10-30, prepared rhizome of rehmannia 10-30, cynomorium songaricum 10-30, fructus gleditsiae sinensis 10-30,cassia twig 5-10, radix patriniae heterophylla 10-15, ladybell root 10-15, root of glutinous rice 10-15, etc.

The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).

According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic/antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.

This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses compositions, methodologies, and delivery mode for the utilization of probiotic organisms in therapeutic compositions for treatment and relief from the symptoms of urogenital infections by maintaining and restoring normal flora in humans. The composition includes one or more bacteria selected from the genus Lactobacillus. More specifically, the invention relates to the utilization of one or more species or strains of Lactobacillus producing bacteria for the control of urinary tract bacteria and pathogens, including antibiotic-resistant urinary tract pathogens, and their associated diseases by both a reduction in the rate of colonization of the infection and pathogens. The method for treatment and relief from symptoms includes administration via a rectal suppository with a safe and effective amount of the composition. The delivery mode for administering the probiotic is via a rectal suppository. The delivery through the rectum provides an optimum method of transmission of the treatment.

Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding symptoms, decreasing inflammation and prostate size, reducing cellular proliferation in prostate tissue, and/or reducing PSA levels to within the normal range of 0-4.

The invention discloses an externally used nanometer silver antibiotic jel line products, which is characterized by the following: constituting with acceptable shaped agent, diluent, slow releasing agent, disperser on nanometer silver and medicinal; setting the grain size of the nanometer silver at 1-25nm; comprising push injecting agent, foam spray, aquagel cleaning solvent, spray and so on of nanometer silver antibiotic jel line products. This invention also relates to the preparing method of nanometer silver colloid and nanometer silver antibiotic jel line products. This product can be used to cure vaginitis, cervicitis, mixing infection type gynaecologic inflammation, prostatitis, prostate proliferation, prostatauxe, male urethritis, balanitis, posthitis and so on.

This invention describes the use of beta-3-adrenoceptor agonists for the treatment of disorders associated with the prostate. These include disorders like those occurring in a prostatitis, where attributable to inflammatory processes or chronic irritation, or disorders like those associated with benign changes of the prostate. The invention is particularly suitable for the treatment of benign prostatic hyperplasia (BPH).

The invention relates to the field of medicinal chemistry, and discloses three crystal forms of cabazitaxel, i.e., an ester compound crystal form J of cabazitaxel, a hydrate crystal form G of cabazitaxel and a cabazitaxel crystal form I, and a preparation method of a novel crystal form of cabazitaxel. The novel cabazitaxel form has superior performance on the aspects of oral absorptivity, activation of metabolism and suppression of mitosis and interval cell function of cells, is weak in toxicity, has high storing and treating stability, and can be applied to preparation of a medicament for treating prostatitis.

A disinfecting nano silver gel for treating bacterial vaginitis, prostatitis, burn, scald, wound, etc. contains pharmacologically receptable additive, carrier, and broad-spectrum antibacterial nano silver particles (0.1-0.4%) with 1-100 nm of granularity.

The invention discloses a Chinese medicament for treating prostatitis, which is characterized in that the Chinese medicament is prepared from plantain seed, safflower, corktree bark, epimedium, red paeony root, anemarrhena root, achyranthes root, tuckahoe, dodder seed, cynomorium, hiraute shiny bugleweed herb, oriental waterplantain rhizome, many-flower solomonseal rhizome, Chinese yam, gentian, Szechwan chinaberry fruit, rush, mantis egg-case, medlar, dandelion, lotus plumule, cowherb seed, astragalus, loranthus parasiticus, barbed skullcap herb and clematis stem in a certain ratio. Aiming at the chronic prostatitis symptom, the Chinese medicament treats the rout causes at the same time of treating the urinary tract symptom; and the Chinese medicament for treating the prostatitis has good effects of activating blood and dissolving stasis, diminishing inflammation and relieving pain, clearing heat and detoxifying, promoting qi circulation and removing retention, promoting urination and treating stranguria, meanwhile increases human immunity and resists bacteria regeneration.

A Chinese medicine in the form of adhesive plaster for treating prostatitis is prepared from 14 Chinese-medicinal materials including peach kernel, red sage root, honeysuckle flower, red peony root, etc. Its advantages are high curative effect and very low by-effect.

The invention discloses traditional Chinese medicine health-care tea and a preparation method thereof. The traditional Chinese medicine health-care tea is prepared from the following raw materials in parts by weight: 6-12 parts of American ginseng, 6-12 parts of lucid ganoderma, 10-15 parts of Astragalus membranaceus, 6-12 parts of the fruit of Chinese wolfberry, 6-12 parts of Chinese-date, 3-6 parts of liquorice, 6-10 parts of Angelica sinensis and 6-9 parts of radix paeoniae alba. The traditional Chinese medicine health-care tea has the effects of regulating the middle warmer and tonifying stomach, tonifying the liver and kidney and reinforcing qi and nourishing blood, can treat or relieve insomnia, neurasthenia and the like and condition internal secretion, and improves the immunity of body and enhances resistance, and in particular has a remarkable treatment effect to symptoms such as constipation, dizziness, headache and lassitude as well as remarkable treatment and prevention functions to diseases such as prostatitis, impotence and colonitis.

The invention discloses health-care medicinal liquor with the function of invigorating kidney and a preparation method thereof which belong to the technical field of traditional Chinese medicine. The health-care medicinal liquor is prepared from the following raw materials in weight portion: distilled spirit, and Chinese herbal medicines of aweto, ginseng, fructus schizandrae, medlar, actinolite, male silk moth, astragalus root, herba epimedii, herba cistanches, semen alli tuberosi, yam and tuckahoe. The total effective rate of the health-care medicinal liquor for renal deficiency, renal hypofunction patients, nephropathy, prostatitis, rheumatoid arthritis, cervical spondylopathy and lumbar intervertebral disc protrusion can reach over 90 percent. The health-care medicinal liquor also has auxiliary treatment and health-care function on gastritis, gastric cold, intestinal inflammation, irregular menses, adnexitis, hyperplasia of mammary glands, hypopiesis and arrhythmia. The health-care medicinal liquor has a simple concoction process, available material source, no risk in production, transportation and storage, and wide market prospect.

The invention provides health-care cold tea prepared mainly from honeysuckle and Camellia nitidissima and a preparation method thereof. The invention adopts a technical scheme that: ingredients of the health-care cold tea comprise 10 to 90 percent of honeysuckle and 90 to 10 percent of Camellia nitidissima; and the preparation method comprises the step of grinding the honeysuckle and Camellia nitidissima into powder respectively or grinding the honeysuckle and Camellia nitidissima into powder by using a supermicron milling technique, stirring uniformly, and packing by 2 to 10 gram bags. In the invention, the honeysuckle and Camellia nitidissima are ground into powder by the supermicron milling technique, so the nutrient utilization rate is high, and the tea is convenient to drink; and the tea has the effects of clearing heat, detoxifying, resisting bacteria and inflammation, regulating immunity, promoting dieresis and diminishing swelling, is rich various natural nutrients such as tea polyphenol, protodioscin, total flavonoids, tea polysaccharide, tea pigment, caffeine, vitamin and amino acid, contains various trace elements such natural organic germanium (Ge), selenium (Se), molybdenum (Mo), zinc (Zn) and the like, and has the health-care functions of preventing cancer, inhibiting tumor growth, reducing blood fat and cholesterol, preventing atherosclerosis, preventing prostatitis, supplying nutrients, in habiting bacteria and resisting aging, and is suitable for all people.

The invention relates to suspensoid powder injection of an amoxicillin sodium sulbactam sodium medicine composition and a preparation method thereof. The suspensoid powder injection contains Tween 80, cholesterol, deoxysodium cholate, a freeze-drying support agent and active components. The invention also relates to a novel application of the suspensoid powder injection in preparing a medicine treating prostatitis further.

The invention relates to a medicament for treating a prostatic disease, which is prepared from the following Chinese medical herbs in parts by weight: 40-60 parts of rehmanniae praeparatum, 40-60 parts of rehmanniae vaporata, 50-70 parts of common macrocarpium fruit, 40-60 parts of epimedium, 40-60 parts of morindae, 40-60 parts of desertliving cistanche, 40-60 parts of south dodder seed, 40-60 parts of malaytea scurfpea fruit, 40-60 parts of common cnidium fruit, 40-60 parts of palmleaf raspberry fruit, 30-50 parts of Chinese magnoliavine fruit, 20-40 parts of cassia bark, 30-50 parts of fennel fruit, 30-50 parts of cervus nippon temminck, 30-50 parts of eucommia bark, 30-50 parts of achyranthes root, 30-50 parts of Indian buead, 30-50 parts of dioscoreae, 30-50 parts of Chinese eaglewood, 40-60 parts of dendrobium, 40-60 parts of scrophularia, 30-50 parts of cluster mallow fruit, 40-60 parts of herba pyrrosiae, 40-60 parts of plantago seed, 40-60 parts of rhizoma anemarrhenae, 40-60 parts of phellodendron, 40-60 parts of white paeony root and 30-50 parts of raw liquorice root, and capsules are prepared by the steps of grinding the Chinese medical herbs into fine powder and encapsuling. The medicament has effects of invigorating yin, supporting yang, resuscitating and treating stranguria and is mainly suitable for chronic prostatitis or prostatic hyperplasia.

The present invention relates to capsule for treating acute and chronic prostatitis and its preparation process, and features that the active components of the medicine is prepared with 14 kinds of Chinese medicinal materials, including angelica, honeysuckle, red sage, licorice, dandelion, etc in certain weight proportion. The present invention has the advantages of reasonable preparation process, reduced dosage, stable technological process, etc. The prostatitis treating capsule has the functions of clearing away heat, promoting diuresis and promoting blood circulation to disperse blood clots, and possesses high curative effect on prostatitis and high safety.

The invention relates to a medicinal composition for treating chronic prostatitis and hypertrophy of the prostate, which is prepared from the following Chinese medicinal herbs: astragalus root, cassia twig, banksia rose, motherwort, epimeddium, rhubarb horsetails, rhizoma dioscoreae, eupatene, lotus seeds, plantain seeds, dandelion, cherokee rose,herba patriniae, giant knotweed rhizome, Chinese pink herb, knotgrass, pyrrosia leaf, paniculate bolbostemma rhizome, talcum, flavescent sophora root, cimicifuga rhizome, sargentgloryvine stem, achyranthes and cyathula root, licorice root, and corktree bark.